Novo Nordisk upgraded at UBS as analysts call CagriSema sell-off "overdone"
Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and is in pole position to benefit from strong near-term demand for new weight-loss drugs, according to analysts at UBS.
Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...
CagriSema, a drug that Novo had hoped would become the next generation weight-loss aid, failed to meet expectations in ...
Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes.
Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...
Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO 0.15%) stock crashed ...
GlobalData on MSN21d
Novo Nordisk takes a hit as CagriSema underperforms in weight lossDanish mega-company Novo Nordisk has taken a hit after its newest experimental weight loss drug, CagriSema, fell short ...
Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.
Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback